Phase II - IV Clinical

Summer Update from the QPS Respiratory Team

The QPS Respiratory Team has now set up a virus model of asthma. Using this exacerbation model, Dr. Tjeert Mensinga, QPS-dedicated Research Physician, is currently including eligible asthmatics in an interventional biomarker study in close collaboration with national and international centers of excellence. Medical Director & Research Pulmonologist Professor Zuzana Diamant and the QPS Respiratory Team are close to finalizing a large multicenter asthma trial, in collaboration with centers in the UK and Germany.

Sophisticated Biomarker Sampling Powered by a Network of Excellence

Partnering with the Global BIOSPIT Initiative Centers of Excellence [Clarke, Diamant et al., PPT 2013], QPS’ dedicated laboratory technicians are working to standardize sputum processing techniques. The aim of harmonizing methodologies across dedicated centers is to enable multicenter trials using induced sputum as a primary outcome measure for asthma and COPD studies.

Meet us at the European Respiratory Society Annual Congress in Barcelona (September 7 - 11, 2013)

Zuzana Diamant will be visiting the ERS Congress and is co-presenting two scientific posters. Please drop by to learn about our respiratory facilities and collaborations. Email:

ERS Abstracts
  • Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis
    Z Diamant
    L Franciosi, N Morelli, R Zuiker, IMC Kamerling, M de Kam, J Burggraaf, AF Cohen, M Walker, and CP Page
    Sunday September 8, 2013: 12.50 - 14.40
  • Effects of low- vs high-dose fluticasone/formoterol combination therapy on AMP challenge in asthmatic patients
    F KanniessZ DiamantM Lomax, and M Jain
    Tuesday September 10, 2013: 10.45 - 12.45
Recent Publications
  • Inhaled Allergen Bronchoprovocation Tests. Review supported by the ATS/ERS Task Force on Bronchoprovocation tests.
    Diamant Z, Gauvreau GM, Cockcroft DW, Boulet LP, Sterk PJ; de Jongh FH, Dahlén B, and O'Byrne PM.
    Journal of Allergy and Clinical Immunology (2013) in press
  • RPL554, a dual PDE3 and PDE4 inhibitor with bronchodilator and anti-inflammatory properties: efficacy and safety in clinical trials in healthy subjects and in patients with asthma or COPD.
    Franciosi L, Diamant Z, Banner KH, et al.
    Lancet Respiratory Medicine (2013) in press
20 years in pharma R&D navigation